Anastrazole

Product Details

This compound is classified as a non-steroidal aromatase inhibitor and is commonly examined in controlled laboratory settings for its interaction with estrogen biosynthesis pathways. It belongs to a class of triazole-containing molecules known for their affinity toward enzymes involved in steroidogenesis.

In research environments, focus is placed on how this compound interacts with enzymatic systems responsible for the conversion of androgenic substrates into estrogenic metabolites. These investigations emphasize molecular binding characteristics and enzyme modulation rather than physiological outcomes.

Additionally, the compound is studied for its structural features, including its nitrile and triazole functional groups, which contribute to its interaction with specific catalytic domains of enzymes.

Mechanism of Action

This compound is investigated for its reversible interaction with the aromatase enzyme, a cytochrome P450-associated enzyme involved in steroid biosynthesis. Aromatase catalyzes the conversion of androgen precursors into estrogenic compounds through oxidative reactions.

Upon binding, the compound is analyzed for its ability to alter enzyme conformation and catalytic activity. This interaction may influence the enzymatic conversion process at the molecular level, thereby affecting substrate processing within the steroidogenic pathway.

Furthermore, its triazole ring structure is associated with coordination to the heme group of the aromatase enzyme. This coordination is a key focus in studies examining enzyme inhibition kinetics and ligand-enzyme binding dynamics.

Chemical Properties

Research Applications

Aromatase Enzyme Inhibition Studies

This compound is widely utilized in research focusing on aromatase enzyme activity. Studies in this area examine how ligand binding influences catalytic function and substrate conversion within steroidogenic pathways.

Steroidogenesis Pathway Analysis

Research involving this compound often explores its role in modulating biochemical pathways associated with steroid hormone synthesis. These investigations focus on enzyme-mediated transformations and regulatory mechanisms at the molecular level.

Enzyme Binding and Kinetics Research

The compound is also examined in studies analyzing enzyme-ligand interactions, including binding affinity, reversibility, and inhibition kinetics. These analyses contribute to a broader understanding of enzyme modulation.

Why Choose BehemothLabz to Buy Aromatase Inhibitor Research Compound (Anastrozole) for Research

BehemothLabz provides research-grade Aromatase Inhibitor Research Compound (Anastrozole) manufactured under controlled laboratory conditions with strict quality assurance protocols. Each batch undergoes analytical verification to ensure consistency in molecular composition and purity.

Comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility in experimental settings. BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research

Disclaimer

Aromatase Inhibitor Research Compound (Anastrozole) is intended strictly for laboratory research and analytical purposes only. It is not intended for use in diagnostic procedures, therapeutic applications, or in vivo studies of any kind.

Any references to biochemical pathways, receptor interactions, or enzymatic processes are provided solely for informational and research-context purposes. This compound must be handled exclusively by qualified professionals in controlled laboratory environments in accordance with applicable regulations and safety guidelines.

Improper handling or use outside of controlled research settings is strictly prohibited.

References

• Vilquin, P., Villedieu, M., Grisard, E., Ben Larbi, S., Ghayad, S. E., Heudel, P. E., Bachelot, T., Corbo, L., Treilleux, I., Vendrell, J. A., & Cohen, P. A. (2013). Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. International journal of cancer, 133(7), 1589–1602. https://doi.org/10.1002/ijc.28182
• Lønning P. E. (2011). The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of oncology : official journal of the European Society for Medical Oncology, 22(3), 503–514. https://doi.org/10.1093/annonc/mdq337 

1st Party COA